BioSpace News Archive

Sareum Holdings plc (AIM: SAR), the specialist drug development company, today announces that it has submitted an application for a Clinical Trial Authorisation (“CTA”) to the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) for the development of SDC-1801 as a potential new therapeutic for a range of autoimmune diseases with a focus on psoriasis.

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the Company will release its second quarter 2022 financial results before the market opens on Thursday, August 11, 2022.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, reported positive topline results from its post-approval study designed to assess the impact on cognitive function in subjects treated with OLINVYK compared to IV morphine.

OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced its ongoing commitment to fight the hepatitis C epidemic.

Lexicon Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001.

Calyxt, Inc., a plant-based synthetic biology company, announced that Michael A. Carr, Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference taking place August 8-11, 2022.

Bausch + Lomb Has Made an Equity Investment in Sanoculis and Has Entered into an Exclusive European Distribution Agreement for MIMS® Minimally Invasive Surgical Procedure.

Kira Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to KP104 for the treatment of Paroxysmal Nocturnal Hemoglobinuria.

Grey Wolf Therapeutics today announced the appointment of Brett Carter as a Non-Executive Director to the board of its Australian subsidiary.

Clinical Enterprise, Inc. announced that it is extending its partnership with Ginkgo Bioworks to continue supporting the Operation Expanded Testing program with the U.S. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, and the U.S. Department of Defense.